Dr. Juan Fueyo
The University of Texas MD Anderson Cancer Center
Department of Neuro-Oncology
My laboratory's projects primarily focus on the development of novel gene therapy strategies for the treatment of malignant gliomas. Specifically, I have been examining the mechanisms of cell- cycle control and cell death that are abrogated in brain tumors. Though working mostly on the P16/Rb (retinoblastoma)/E2F-1 pathway, we are also studying the role of p16, Rb, and E2F-1 as tumor suppressor genes in gliomas. In addition, I am in the process of determining whether conventional chemotherapeutics for gliomas can be enhanced when combined with gene therapy. Another related project involves the determination of proficient means of gene delivery using oncolytic viruses. In this regard, we have identified a replication-competent adenovirus (Delta- 24) that cannot bind the Rb protein, has a potent anticancer effect, and low toxicity in quiescent normal cells. The Delta-24 adenoviral construct is currently the target of a provisional patent and is being further realized into a future clinical trial for patients with malignant brain tumors. The focus of my laboratory over the next two years will be on improving the anticancer effect of oncolytic adenoviruses and the translation of those pre-clinical findings to the clinic setting.
A tutorial in my laboratory would provide a student experience with the general application of the scientific method, cell cycle and apoptosis regulation in cancer, gene therapy techniques including transfection and infection, basic tissue culture procedures, viral vector design, construction and generation, pharmacological and pharmakinetic studies of drugs and drugs combined with proteins, in vitro and in vivo analyses of efficacy and toxicity of any produce (molecular or chemical), and pathologic examination of normal brain and brain tumors.
Office: MDA S5.8316B (Unit 1002)
Title: Associate Professor
M.D. - University Autonomous of Barcelona - 1984